Is perioperative brachytherapy effective in carcinoma of the tongue
Por:
Santos M, Guinot JL, Tortajada M, Vendrell JB, López C, Rosa A, Quiles B, Chust M, Montaner A and Arribas L
Publicada:
1 ene 2022
Ahead of Print:
8 feb 2022
Resumen:
Purpose: To analyze the results of patients treated with perioperative interstitial brachytherapy (ISBT) in tongue carcinoma (TC). Material and methods: From April 2009 to May 2015, 43 squamous cell carcinoma consecutive patients diagnosed with TC were treated with limited partial glossectomy and perioperative ISBT, using high-dose-rate (HDR). Twentyseven patients were treated by brachytherapy (BT), and sixteen received BT as a complement to subsequent external beam radiotherapy (EBRT) after results of lymph node dissection. Median age was 66 years. Distribution by stage, included 10 patients stage I, 14 stage II, 10 stage III, and 9 stage IV. Eighteen patients had negative margins, nineteen margin involvement, and in six cases, the margin was < 5 mm. Results: With a median follow-up of 54 months, LC at 3 and 5 years was 87% and 84%, respectively. LC was 95% at five years in patients with clear margins, and 75% with involved margins. LC in N0 patients treated with BT was 83% at 5 years, and in patients N+ with posterior EBRT treatment, LC was 86%. By tumor size, we found one local relapse in 13 cases T1, in 5 of 27 patients T2 was found, and no local relapse T3 with LC of 87%, 70%, and 100% respectively at five years. Regional control (RC) was 81% at 3 and 5 years. We found a metastasis-free survival of 91% at 3-and 5-year. Twenty-three patients have died, 11 of them due to other causes, with overall survival of 56% at three years and 53% at five years. Conclusions: Combined treatment with conservative surgery and ISBT shows similar results to radical surgery or RT alone, allowing a more patient-tailored approach, with good organ function preservation and cosmetic outcomes.
Filiaciones:
Santos M:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Guinot JL:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Tortajada M:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Vendrell JB:
Department of Otolaryngology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
:
Department of Otolaryngology, Head & Neck Surgery, Hospital Universitario Dr. Peset, Valencia, Spain
Rosa A:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Quiles B:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Chust M:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Montaner A:
Department of Radiation Physics and Radiological Protection, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Arribas L:
Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain
Universidad Católica de Valencia San Vicente Mártir, Spain
gold, Green Published
|